Personalis, Inc. (PSNL): Price and Financial Metrics


Personalis, Inc. (PSNL): $22.75

1.23 (+5.72%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add PSNL to Watchlist
Sign Up

Industry: Biotech


Ranked

of 492

in industry

PSNL POWR Grades


  • Momentum is the dimension where PSNL ranks best; there it ranks ahead of 50.96% of US stocks.
  • The strongest trend for PSNL is in Growth, which has been heading down over the past 199 days.
  • PSNL's current lowest rank is in the Growth metric (where it is better than 9.08% of US stocks).

PSNL Stock Summary

  • PSNL's went public 1.88 years ago, making it older than just 3.1% of listed US stocks we're tracking.
  • The ratio of debt to operating expenses for Personalis Inc is higher than it is for about just 13.5% of US stocks.
  • Personalis Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -30.12%, greater than the shareholder yield of merely 8.89% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Personalis Inc are DSPG, GAN, PING, RAPT, and SGLB.
  • Visit PSNL's SEC page to see the company's official filings. To visit the company's web site, go to www.personalis.com.

PSNL Price Target

For more insight on analysts targets of PSNL, see our PSNL price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $42.00 Average Broker Recommendation 1.5 (Moderate Buy)

PSNL Stock Price Chart Interactive Chart >

Price chart for PSNL

PSNL Price/Volume Stats

Current price $22.75 52-week high $53.46
Prev. close $21.52 52-week low $9.69
Day low $21.72 Volume 583,000
Day high $23.75 Avg. volume 989,238
50-day MA $24.35 Dividend yield N/A
200-day MA $28.33 Market Cap 998.91M

Personalis, Inc. (PSNL) Company Bio


Personalis, Inc. provides genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. The company was founded by Euan A. Ashley, Michael Snyder, Atul J. Butte, John S. West, and Russ B. Altman in 2011 and is headquartered in Menlo Park, CA.


PSNL Latest News Stream


Event/Time News Detail
Loading, please wait...

PSNL Latest Social Stream


Loading social stream, please wait...

View Full PSNL Social Stream

Latest PSNL News From Around the Web

Below are the latest news stories about Personalis Inc that investors may wish to consider to help them evaluate PSNL as an investment opportunity.

Personalis to Present at the 2021 Bank of America Healthcare Conference

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will present at the 2021 Bank of America Healthcare Conference on Thursday, May 13, 2021 at 5:00 p.m. Eastern Time.

Yahoo | April 29, 2021

Personalis Presents Data at AACR Annual Meeting 2021 Showcasing the Personalis ImmunoID NeXT Platform®

Personalis Presents Data at AACR Annual Meeting 2021 Showcasing the Personalis ImmunoID NeXT Platform

Yahoo | April 8, 2021

Personalis (PSNL) Stock Jumps 7.9%: Will It Continue to Soar?

Personalis (PSNL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Yahoo | April 1, 2021

Personalis Announces Changes to its Board of Directors

Personalis Announces Changes to its Board of Directors

Yahoo | March 8, 2021

Personalis Reports Fourth Quarter and Full Year 2020 Financial Results

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, today reported financial results for the fourth quarter and full year ended December 31, 2020.

Yahoo | February 25, 2021

Read More 'PSNL' Stories Here

PSNL Price Returns

1-mo -1.17%
3-mo -43.13%
6-mo -22.72%
1-year 107.95%
3-year N/A
5-year N/A
YTD -37.86%
2020 235.87%
2019 N/A
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.9364 seconds.